健康男性志愿者中恩立妥®技术变更前后的比较研究
健康男性受试者中恩利妥®技术变更前后随机、双盲、平行对照、单剂量药代动力学、安全性与免疫原性对比研究
This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Shanghai、中国
- Shanghai Xuhui Central Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form;
- At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
- Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
- Voluntarily sign the informed consent form.
Exclusion Criteria:
- Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
- Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
- Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
- Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
- Subjects with active infections requiring systemic treatment;
- Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody;
- Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
- Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
- Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
- Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
- Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
- Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
- Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
- Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
- Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
- Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
- Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
- Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
- Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
- Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
- Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug;
- Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:New technology Enlituo
treated with new technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
|
有源比较器:Approved technology Enlituo
treated with Approved technology Enlituo through single intravenous drip |
250 mg/m^2, single intravenous drip |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AUC0-∞
大体时间:From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve extrapolated to infinity |
From enrollment to the end of treatment at 28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AUC0-t
大体时间:From enrollment to the end of treatment at 28 days
|
Area under the concentration time curve from time zero to the last measurable time point. |
From enrollment to the end of treatment at 28 days
|
|
Cmax
大体时间:From enrollment to the end of treatment at 28 days
|
Peak concentration. |
From enrollment to the end of treatment at 28 days
|
|
Tmax
大体时间:From enrollment to the end of treatment at 28 days
|
time to peak |
From enrollment to the end of treatment at 28 days
|
|
t1/2
大体时间:From enrollment to the end of treatment at 28 days
|
half-life |
From enrollment to the end of treatment at 28 days
|
|
λz
大体时间:From enrollment to the end of treatment at 28 days
|
Terminal Elimination Rate Constant |
From enrollment to the end of treatment at 28 days
|
|
CL
大体时间:From enrollment to the end of treatment at 28 days
|
clearance |
From enrollment to the end of treatment at 28 days
|
|
Vd
大体时间:From enrollment to the end of treatment at 28 days
|
volume of distribution |
From enrollment to the end of treatment at 28 days
|
|
Immunogenicity
大体时间:From enrollment to the end of treatment at 28 days
|
Anti-drug antibody positive rate |
From enrollment to the end of treatment at 28 days
|
|
Adverse Event
大体时间:From enrollment to the end of treatment at 6 months
|
Incidence and Severity of Adverse Events |
From enrollment to the end of treatment at 6 months
|
合作者和调查者
调查人员
- 首席研究员:Jingying Jia, PhD、Xuhui Central Hospital, Shanghai
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- CMAB009-C-102
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
After the study result is published, email the application registration contact or the study leader to obtain it.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.